If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Cyramza Summary of Product Characteristics (SmPC)
Cyramza® (ramucirumab): Storage and Stability of Vials In Use
From a microbiological point of view, ramucirumab should be used immediately. Storage prior to use is the responsibility of the user. Chemical and physical in-use stability has been demonstrated for 24 hours at 2 ºC to 8 ºC or for 4 hours at 25 ºC.
infusion solution should be prepared using aseptic technique to
ensure the sterility of the prepared solution.1
prepared as directed, infusion solutions of ramucirumab contain no
and physical in-use stability of ramucirumab in sodium chloride 9
mg/ml (0.9%) solution for injection has been demonstrated for 24
hours at 2 ºC to 8 ºC or for 4 hours at 25 ºC. From a
microbiological point of view, the product should be used
immediately. If not used immediately, in-use storage times and
conditions prior to use are the responsibility of the user and would
normally not be longer than 24 hours at 2 ºC to 8 ºC,
unless dilution has taken place in controlled and validated aseptic
infusion solution should not be frozen or shaken.1
medicinal products should be inspected visually for particulate
matter prior to administration. If particulate matter is identified,
the infusion solution should be discarded.1
unused portion of ramucirumab left in a vial should be discarded, as
the product contains no antimicrobial preservatives.1
Cyramza [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Date of Last Review:August 07, 2020
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org